[{"data":1,"prerenderedAt":159},["ShallowReactive",2],{"drug-ubrogepant":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":72,"warnings":82,"renal":83,"monitoring":84,"interactions":85,"review":86,"examples":89,"atc":95,"iran":97,"usApproval":104,"links":110,"populations":124},"ubrogepant",1,{"fa":7,"en":8},"اوبروجپانت","Ubrogepant","nervous-system",{"fa":11,"en":12},"آنتاگونیست گیرنده CGRP (ژپانت)","CGRP receptor antagonist (gepant)",[14],{"name":15,"market":16},"Ubrelvy","US",[18,19,7],"ubrelvy","اوبرلوی",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[16],[32],{"source":33,"section":34},"fda-ubrelvy","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-100","100 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},100,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":56,"limits":59,"notes":63},"acute","migraine-acute",{"fa":48,"en":49},"حمله حاد میگرن — ۵۰ یا ۱۰۰ mg؛ دوز دوم دست‌کم ۲ ساعت بعد (حداکثر ۲۰۰ mg\u002F۲۴ ساعت)","Acute migraine — 50 or 100 mg; a second dose ≥2 h later (max 200 mg\u002F24 h)",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":5},[57],{"source":33,"section":58},"2.1",{"maxPerDay":60,"refs":61},200,[62],{"source":33,"section":58},[64],{"text":65,"refs":68},{"fa":66,"en":67},"درمان بیش از ۸ میگرن در ۳۰ روز بررسی نشده. نارسایی شدید کبد یا کلیه: ۵۰ mg.","Treating more than 8 migraines in 30 days not studied. Severe hepatic or renal impairment: 50 mg.",[69,70],{"source":33,"section":58},{"source":33,"section":71},"2.2",[73],{"id":74,"severity":75,"text":76,"refs":79},"ci","block",{"fa":77,"en":78},"مهارکننده قوی CYP3A4 همزمان؛ سابقه حساسیت جدی به اوبروجپانت.","Concomitant strong CYP3A4 inhibitors; history of serious hypersensitivity to ubrogepant.",[80],{"source":33,"section":81},"4",[],[],[],[],{"status":87,"reviewer":88,"date":88},"unverified",null,[90],{"regimen":45,"formulation":22,"input":91,"expect":94},{"ageYears":92,"weightKg":93},35,65,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},[96],"N02CD04",{"status":98,"refs":99},"not-found",[100],{"source":101,"section":102,"url":103},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Ubrogepant",{"kind":105,"refs":106,"id":109},"NDA",[107],{"source":33,"section":108},"SPL approval \u002F marketing category","NDA211765",[111,114,118,121],{"kind":112,"url":113,"label":109},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=211765",{"kind":115,"url":116,"label":117},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab","FDA Ubrelvy",{"kind":119,"url":120,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa620016.html",{"kind":122,"url":123,"label":96},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CD04",{"pregnancy":125,"lactation":134,"pediatric":142,"geriatric":151},{"level":126,"text":127,"quote":130,"refs":131},"caution",{"fa":128,"en":129},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women.",[132],{"source":33,"section":133},"8.1",{"level":126,"text":135,"quote":138,"refs":139},{"fa":136,"en":137},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Data from a lactation study in twelve healthy adult females indicate that ubrogepant is excreted in breast milk in low amounts.",[140],{"source":33,"section":141},"8.2",{"level":143,"text":144,"quote":147,"refs":148},"not-established",{"fa":145,"en":146},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[149],{"source":33,"section":150},"8.4",{"level":126,"text":152,"quote":155,"refs":156},{"fa":153,"en":154},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.",[157],{"source":33,"section":158},"8.5",1792156198693]